With the increasing availability and acceptance of real-world evidence outside of academic and institutional settings, community oncology practices are becoming significant and important consumers of this information. Real-world evidence is changing the way regulatory and clinical decisions are evaluated and made, including: demonstration of a therapy’s effectiveness, label expansions, patient outcomes, support for clinical trial results, and changes to product administration protocols, according to a recent presentation delivered by Sarah Alwardt, PhD, Vice President of Data, Evidence & Insights for McKesson Life Sciences, and Nicholas Robert, MD, Medical Director of Data, Evidence & Insights for McKesson Life Sciences and The US Oncology Network.